Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Glioma 6Glioblastoma 3Insulinoma 2Hypoglycemia 2Hyperinsulinism 2Congenital Hyperinsulinism 2Brain Neoplasms 2Sarcoma 1Pheochromocytoma 1Parkinsonian Disorders 1Parkinson Disease 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1Lewy Body Disease 1Infant, Newborn, Diseases 1Glucose Metabolism Disorders 1Gliosarcoma 1Glioma, Subependymal 1Ependymoma 1Endocrine System Diseases 1Carcinoma, Medullary 1Carcinoid Tumor 1Beckwith-Wiedemann Syndrome 1Astrocytoma 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × fluorodopa F 18 × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡